-
In April 2022, the Crohn’s and Colitis Foundation provided funding to Microbiotica through its Inflammatory Bowel Disease Ventures Program. This investment is intended to accelerate Microbiotica’s research efforts aimed at developing new therapeutic solutions for managing Crohn’s disease and ulcerative colitis. The funding is expected to advance innovative treatment options, potentially improving patient outcomes and expanding the market for inflammatory bowel disease therapies
- In the same month, Engitix expanded its partnership with Takeda to enhance the discovery and development of novel therapeutics for fibrostenotic inflammatory bowel diseases, including Crohn’s disease. This collaboration leverages Engitix’s tissue modeling expertise alongside Takeda’s therapeutic development capabilities, aiming to address significant unmet medical needs. The partnership is poised to drive innovation in treatment strategies, positively impacting the Crohn’s disease market by offering more effective management options
